Austin, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Dementia Treatment Market Size & Growth Outlook
According to SNS Insider, the global Dementia Treatment Market was valued at USD 17.06 billion in 2023 and is projected to reach USD 33.54 billion by 2032, expanding at a CAGR of 7.80% from 2024–2032. The U.S. Dementia Treatment Market accounted for USD 5.35 billion in 2023 and is expected to almost double to USD 10.50 billion by 2032, growing at a CAGR of 7.77%. This growth is being accelerated by an aging global population, increased clinical adoption of novel Alzheimer’s therapies, and government-backed awareness initiatives.
Get Free Sample Report of the Dementia Treatment Market: https://www.snsinsider.com/sample-request/6780
Dementia Treatment Market Overview
Dementia encompasses multiple cognitive disorders, with Alzheimer’s disease being the most prevalent. Growing prevalence, improved diagnostic capabilities, and a strong pipeline of disease-modifying drugs are shaping the treatment landscape. In the U.S., the FDA’s accelerated approvals for innovative therapies have further boosted investments, while European and Asia-Pacific countries are intensifying efforts through national dementia strategies.
Major Players Analysis Listed in this Report are:
- Biogen Inc. (Aduhelm, Leqembi)
- Eisai Co., Ltd. (Leqembi, Aricept)
- Eli Lilly and Company (Donanemab, Zyprexa)
- Roche Holding AG (Gantenerumab, Ocrevus)
- Novartis AG (Exelon Patch, Memantine)
- Pfizer Inc. (Aricept, Zoloft)
- Johnson & Johnson (Namenda XR, Risperdal)
- Merck & Co., Inc. (MK-8931, Belsomra)
- AbbVie Inc. (Depakote, Namzaric)
- Otsuka Pharmaceutical Co., Ltd. (Brexpiprazole, Aripiprazole)
- Takeda Pharmaceutical Company Ltd. (Brintellix, Memary)
- Lundbeck A/S (Ebixa, Rexulti)
- Amgen Inc. (ABP 654, Aimovig)
- Teva Pharmaceutical Industries Ltd. (Donepezil Teva, Rivastigmine Capsules)
- Sun Pharmaceutical Industries Ltd. (Memantine Sun, Donepezil Sun)
- Dr. Reddy’s Laboratories (Memantine Tablets, Donepezil Hydrochloride)
- Zydus Lifesciences Ltd. (Donecept, Memasure)
- Intas Pharmaceuticals Ltd. (Rivamer, Donetaz)
- Torrent Pharmaceuticals Ltd. (Donepez, Memtor)
- Cipla Ltd. (Donetec, Memantha)
Dementia Treatment Market Report Scope
| Report Attributes | Details |
| Market Size in 2023 | US$ 17.06 Billion |
| Market Size by 2032 | US$ 33.54 Billion |
| CAGR | CAGR of 7.80% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Regional Analysis | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
Segment Analysis
Alzheimer's Disease Dementia Segment Dominated the Market, By Indication
The Alzheimer's disease dementia segment held the largest share of the 2023 dementia treatment market, and accounted for 60.14% market share because Alzheimer's disease is more common than other types of dementia. Alzheimer's disease is the most common cause of dementia worldwide, accounting for 60–80% of dementia cases, which is why it is the first target of dementia diagnosis, research, and treatment, according to the Alzheimer's Association. Ample money for the development of drugs, strong pipelines for clinical trials, and increased public awareness campaigns all favor the segment.
Cholinesterase Inhibitors Segment Dominated the Market by Drug Class
The cholinesterase inhibitors segment dominated the dementia treatment market with a 45.19% in 2023, as it has been the first-line pharmacological treatment for Alzheimer’s disease and for other types of dementia for an extended period of time. These drugs (donepezil, rivastigmine, and galantamine), clinically proven to enhance cognitive performance and delay symptomatic progression in mild to moderate cases. As they have been in use for many years with well-established efficacy and safety profiles and are included in treatment guidelines across the globe, continuing demand is guaranteed.
For a Personalized Briefing with Our Industry Analysts, Connect Now: https://www.snsinsider.com/request-analyst/6780
Dementia Treatment Market Segmentation
By Indication
- Alzheimer’s Disease Dementia
- Vascular Dementia
- Lewy Body Dementia
- Frontotemporal Dementia (FTD)
- Parkinson's Disease Dementia
- Others
By Drug Class
- Cholinesterase Inhibitors
- NMDA Receptor Antagonist
- MAO Inhibitors
- Combination Drug
- Others
By Route of Administration
- Oral
- Transdermal Patch
- Injectable
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
The Dementia Treatment Market in North America is the largest, Asia-Pacific region is estimated to register the highest growth during the forecast period
North America led the dementia treatment market with a 38.12% market share in 2023, owing to better healthcare services, high diagnosis rates, and research and development in this region. The number of Americans aged 65 and older living with Alzheimer’s was over 6.9 million in 2024, according to the Alzheimer’s Association. Solid government financing, large pharmaceutical sectors, and the advent of innovative treatments also help keep the region firmly at the forefront of this market.
The fastest growth in the Asia region during the projection period is anticipated to occur with an 8.27% CAGR over the forecast period as a result of growing aging populations, higher awareness of dementia, and wider accessibility of health care. The Netherlands and China are bang for the time being, witnessing fast demographic transitions with a rising fraction of elderly inclined to lose. Public health initiatives and investments in neurological research are also speeding up the adoption of early diagnosis and treatment. Moreover, growth in the middle class and increasing healthcare costs in emerging economies are anticipated to promote the market in the region.
Buy the Full Dementia Treatment Market Report (Single-User License) Now: https://www.snsinsider.com/checkout/6780
Unique Selling Propositions (USPs) of the Report:
- Patient Journey & Care Pathway Mapping
Helps identify key intervention points and optimize treatment strategies based on real-world patient progression patterns.
- Therapy Pipeline Feasibility & Competitive Readiness Index
Enables the client to gauge upcoming competition and assess the commercial viability of emerging dementia therapies.
- Regional Reimbursement & Policy Landscape Matrix
Guides market entry and pricing strategies by mapping region-specific reimbursement frameworks and regulatory policies.
- Clinical Trials Heat Map & Success Probability Analysis
Prioritizes investment and partnership decisions by identifying high-potential clinical programs and geographic trial hotspots.
- Adoption Barriers & Behavioral Economics in Treatment Uptake
Uncovers psychological and systemic factors hindering adoption, helping refine patient engagement and awareness campaigns.
- Digital Health & AI Intervention Tracker
Tracks innovative AI-enabled and digital solutions, allowing the client to leverage new tech-driven opportunities for dementia management.
- Stakeholder Sentiment Analysis
Captures opinions from physicians, caregivers, and payers to shape positioning, messaging, and stakeholder engagement strategies.
Access Complete Report Details of Dementia Treatment Market Analysis & Outlook@ https://www.snsinsider.com/reports/dementia-treatment-market-6780/
[For more information or need any customization research mail us at info@snsinsider.com]
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
